Search
forLearn
5 / 801 resultslearn vividine
learn phenylanine
learn phenoxyethanol
learn gentian
Research
5 / 1000+ resultsresearch Cases update: international roundup of recently filed cases and noteworthy rulings
Recent legal rulings favored Genentech, Teva, and upheld guidelines for patent term extensions.
research Patentability of dosage regime invention in the form of Swiss-type claim under Chinese patent law
Dosage regime inventions can be patentable in China, but legal uncertainty exists.
research UK High Court Revokes Escitalopram UK Patent; Validity of Second Medical use Claims Based on Dosage Regimes in the UK; Stay of Proceedings in the UK Courts Pending EPO Opposition Proceedings
The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.
research Court of Appeal can overrule itself to follow the EPO: UK adopts EPO stance on second medical use claims
The UK Court of Appeal ruled that new dosing regimens for drugs can be patented, aligning with the European Patent Office's approach.
research Does the law provide effective equality rights for people with a visible difference in the workplace?
UK law does not effectively ensure workplace equality for people with visible differences.
Community Join
5 / 1000+ resultscommunity Mildly Interesting: Kintor removes the annotation that pictures are from clinical experiments and that KX-826 gives "real" visible results, editing their Amazon page once again
Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
community Juicero is not an analogy for PP405. Stop bringing that up.
PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.